

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Virtua Health System-West Jersey Hospital</p> <p>2. 101 Carnie Boulevard Voorhees, New Jersey 08043</p>	<p>In accordance with the letter dated February 15, 2008,</p> <p>3. License number 29-01862-02 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date December 31, 2010</p> <hr/> <p>5. Docket No. 030-02443 Reference No.29-15615-01</p>
---	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.400</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed sources</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 1000 millicuries</p> <p>D. 2000 millicuries</p>
--	--	---

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.
 - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
 - D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

CONDITIONS

- 10. A. Licensed material may be used or stored at the licensee's facilities located at Virtua West Jersey Hospital Marlton, 90 Brick Road, Marlton, New Jersey.
- B. Licensed material in Items 6.A., 6.B., and 6.C. may be used or stored at the licensee's facilities located at Virtua West Jersey Hospital Voorhees, 101 Carnie Blvd, Voorhees, New Jersey.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
29-01862-02

Docket or Reference Number
030-02443/29-15615-01

Amendment No. 57

- C. Licensed material in Items 6.A. and 6.B. may be used or stored at the licensee's facilities located at Virtua West Jersey Hospital Berlin, 100 Townsend Avenue, Berlin, New Jersey.
- D. Licensed material in Item 6.C. may be used or stored at Fox Chase Virtua Health Cancer Center Voorhees, 106 Carnie Blvd., Suite A, Voorhees, New Jersey.
11. The Radiation Safety Officer for this license is Daniel J. Januscki, M.Sc.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Mark Goldenberg, M.D.

35.100; 35.200; 35.300; 35.400

Frank Petrovick, M.D.

35.100; 35.200; oral administration of sodium iodide I-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction; 35.400

Edward Petrella, M.D.

35.100; 35.200; 35.300

Paul Curtis, M.D.

35.100; 35.200; 35.300

Vincent Limcaoco, M.D.

35.100; 35.200; oral administration of sodium iodide I-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction

John Curtis, M.D.

35.100; 35.200

Alfio Pennisi, M.D.

35.100; 35.200

Thomas Sergi, M.D.

35.100; 35.200; oral administration of sodium iodide iodine-131 for treatment of thyroid carcinoma

Mark S. Dannenbaum, M.D.

35.100; 35.200; oral administration of sodium iodide iodine-131 for treatment of thyroid carcinoma

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
29-01862-02

Docket or Reference Number
030-02443/29-15615-01

Amendment No. 57

Authorized Users

Material and Use

Jerry Apple, M.D.

35.100; 35.200; oral administration of sodium iodide I-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction

William F. Muhr, Jr., M.D.

35.100; 35.200

Edward Podgorski, Jr., M.D.

35.100; 35.200

Neil Kramer, M.D.

35.100; 35.200; oral administration of sodium iodide I-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction

William F. Rosner, M.D.

35.100; 35.200

Lewis R. Samuel, M.D.

35.100; 35.200; oral administration of sodium iodide I-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction

Barry Shurman, M.D.

35.100; 35.200

James Elder, M.D.

35.100; 35.200

Susan Beth Oberlender, M.D.

35.100; 35.200

Linda Schmucker, M.D.

35.100; 35.200

Thomas Niedbala, M.D.

35.100; 35.200

Carolyn J. Horowitz, M.D., Ph.D.

35.400

David H. Kramer, M.D.

35.100; 35.200

Kevin T. Bufalino, M.D.

35.100; 35.200

Lemuel S. Ariaratnam, M.D.

35.300, except iodine-131; 35.400

Kelly D. Fife, M.D.

35.300, except iodine-131; 35.400

Randall Snyder, M.D.

35.100; 35.200; 35.300

Melvin Markowitz, M.D.

35.100; 35.200

Jamil Mohsin, M.D.

35.100; 35.200; 35.300

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
29-01862-02

Docket or Reference Number
030-02443/29-15615-01

Amendment No. 57

Authorized Users

Material and Use

Alexis Harvey, M.D.

35.400

Ashraf Yousef, M.D.

35.400

Helaina Semmler, M.D.

35.100; 35.200; 35.300

Deborah Butzbach, M.D.

35.300, except iodine-131

John Wilson, M.D.

Parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV, permitted by 10 CFR 35.300; 35.400

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing financial assurance for decommissioning.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
29-01862-02Docket or Reference Number
030-02443/29-15615-01

Amendment No. 57

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Letter dated August 25, 2000 (ML003746998)
 - B. Letter dated September 25, 2000
 - C. Letter dated October 4, 2000 except Quality Management Program (ML003748074)
 - D. Letter dated November 13, 2000 (ML003771603)
 - E. Letter dated March 14, 2001 (ML010800066)
 - F. Letter dated May 3, 2002 (ML021400249)
 - G. Letter received January 22, 2004 (ML040410691)
 - H. Letter dated February 18, 2004 (ML040700266)
 - I. Letter dated February 15, 2008 (ML080850188)
 - J. Letter dated May 12, 2008 (ML081490560)

For the U.S. Nuclear Regulatory Commission

Date May 30, 2008By ***Original signed by Sandra Gabriel***

Sandra Gabriel
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406